L

ate last year, the Colombian Health Ministry unilaterally lowered the price of a Novartis cancer drug by 44 percent, a controversial step that underscored growing tensions between cash-strapped governments and the pharmaceutical industry. Now, though, a different branch of the Colombian government is trying to make it harder for such a move to occur again.

The Ministry of Trade, Industry, and Tourism earlier this month released a draft decree that would establish additional procedures before the government could either unilaterally cut the price of a medicine or issue a compulsory license, which would allow the government to sidestep patents held by a brand-name drug maker and allow another company to make a lower-cost version.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.